Apixaban Dosage
Medically reviewed by Drugs.com. Last updated on Sep 20, 2019.
Applies to the following strengths: 2.5 mg; 5 mg
Usual Adult Dose for:
- Deep Vein Thrombosis - Prophylaxis
- Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery
- Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery
- Prevention of Thromboembolism in Atrial Fibrillation
- Thromboembolic Stroke Prophylaxis
- Deep Vein Thrombosis
- Pulmonary Embolism
Additional dosage information:
Usual Adult Dose for Deep Vein Thrombosis - Prophylaxis
DEEP VEIN THROMBOSIS (DVT) PROPHYLAXIS FOLLOWING HIP OR KNEE REPLACEMENT SURGERY:
2.5 mg orally twice a day
Duration of therapy:
-Hip replacement: 35 days
-Knee replacement: 12 days
Comments: The initial dose should be taken 12 to 24 hours after surgery.
Use: Prophylaxis of DVT, which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
RECURRENT DVT AND PE RISK REDUCTION:
2.5 mg orally twice a day
Use: Reduction in the risk of recurrence of DVT and PE after at least 6 months of treatment for DVT or PE.
Usual Adult Dose for Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery
DEEP VEIN THROMBOSIS (DVT) PROPHYLAXIS FOLLOWING HIP OR KNEE REPLACEMENT SURGERY:
2.5 mg orally twice a day
Duration of therapy:
-Hip replacement: 35 days
-Knee replacement: 12 days
Comments: The initial dose should be taken 12 to 24 hours after surgery.
Use: Prophylaxis of DVT, which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
RECURRENT DVT AND PE RISK REDUCTION:
2.5 mg orally twice a day
Use: Reduction in the risk of recurrence of DVT and PE after at least 6 months of treatment for DVT or PE.
Usual Adult Dose for Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery
DEEP VEIN THROMBOSIS (DVT) PROPHYLAXIS FOLLOWING HIP OR KNEE REPLACEMENT SURGERY:
2.5 mg orally twice a day
Duration of therapy:
-Hip replacement: 35 days
-Knee replacement: 12 days
Comments: The initial dose should be taken 12 to 24 hours after surgery.
Use: Prophylaxis of DVT, which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
RECURRENT DVT AND PE RISK REDUCTION:
2.5 mg orally twice a day
Use: Reduction in the risk of recurrence of DVT and PE after at least 6 months of treatment for DVT or PE.
Usual Adult Dose for Prevention of Thromboembolism in Atrial Fibrillation
5 mg orally 2 times a day
Use: Reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Usual Adult Dose for Thromboembolic Stroke Prophylaxis
5 mg orally 2 times a day
Use: Reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Usual Adult Dose for Deep Vein Thrombosis
Initial dose: 10 mg orally 2 times a day for 7 days
Maintenance dose: 5 mg orally 2 times a day
Use: Treatment of deep vein thrombosis and pulmonary embolism.
Usual Adult Dose for Pulmonary Embolism
Initial dose: 10 mg orally 2 times a day for 7 days
Maintenance dose: 5 mg orally 2 times a day
Use: Treatment of deep vein thrombosis and pulmonary embolism.
Renal Dose Adjustments
Stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation:
-Reduce dose to 2.5 mg orally 2 times a day for patients with any 2 of the following:
--Age 80 years or older
--Body weight 60 kg or less
--Serum creatinine 1.5 mg/dL or higher
Deep vein thrombosis prophylaxis after hip or knee replacement: No adjustment required.
Deep vein thrombosis (DVT) and pulmonary embolism (PE) treatment: No adjustment required.
Recurrent DVT and PE risk reduction: No adjustment required.
Liver Dose Adjustments
Mild liver impairment (Child-Pugh A): No adjustment recommended
Moderate liver impairment (Child-Pugh B): These patients may have intrinsic coagulation abnormalities and there is limited experience with apixaban in these patients; therefore, data is not available.
Severe liver impairment (Child-Pugh C): Not recommended
Dose Adjustments
Coadministration with strong dual CYP450 3A4 and P-gp inhibitors:
-Patients receiving over 2.5 mg orally 2 times a day: Reduce dose by 50%
-Patients receiving 2.5 mg orally 2 times a day: Avoid coadministration
Nonvalvular atrial fibrillation patients:
-Reduce dose to 2.5 mg orally 2 times a day for patients with any 2 of the following:
--Age 80 years or older
--Body weight 60 kg or less
--Serum creatinine 1.5 mg/dL or higher
Precautions
The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for apixaban. It includes a communication plan. For additional information: www.fda.gov/REMS
US BOXED WARNINGS:
PREMATURE DISCONTINUATION INCREASES THE RISK OF THROMBOTIC EVENTS:
-Premature discontinuation of any anticoagulant increases the risk of thrombotic events.
-To reduce this risk, consider coverage with another anticoagulant if apixaban is discontinued for a reason other than pathological bleeding or completion of therapy.
SPINAL/EPIDURAL HEMATOMA:
-Epidural or spinal hematomas may occur in patients treated with apixaban who are receiving neuraxial anesthesia or undergoing spinal puncture.
-These hematomas may result in long term or permanent paralysis.
-Consider these risks when scheduling patients for spinal procedures.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Hemodialysis:
Nonvalvular atrial fibrillation patients with end stage renal disease: 5 mg orally 2 times a day
Reduce dose to 2.5 mg orally 2 times a day if patient is 80 years or older OR body weight is 60 kg or less.
Deep vein thrombosis prophylaxis after hip or knee replacement: No adjustment required.
Deep vein thrombosis (DVT) and pulmonary embolism (PE) treatment: No adjustment required.
Recurrent DVT and PE risk reduction: No adjustment required.
Other Comments
Administration advice:
-May take with or without food.
-Missed dose: Take as soon as possible on the same day then resume twice daily administration. Do not double up to make up for a missed dose.
-Stop medication 48 hours prior to surgery or invasive procedures with moderate to high risk of unacceptable or clinically significant bleeding.
-Stop medication 24 hours prior to surgery or invasive procedures with low bleeding risk or where bleeding would be in a non-critical location and easily controlled.
-Bridging anticoagulation is generally not required.
-Restart after surgery/procedure as soon as adequate hemostasis has been established.
-Patients unable to swallow whole tablets: The manufacturer product information should be consulted.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about apixaban
- Side Effects
- During Pregnancy or Breastfeeding
- Patient Tips
- Imprints, Shape & Color Data
- Drug Interactions
- En Español
- 183 Reviews
- Drug class: factor Xa inhibitors
- FDA Alerts (1)
Consumer resources
Other brands: Eliquis